Glivec Research Today is a free monthly online journal that collates and summarizes the latest research about Glivec, including details on gleevec, imatinib, cancer, treatment, side-effects.

Volume 2 (2005), Issue 2 (February)

1. Accessing key steps of human tumor progression in vivo by using an avian embryo model.
   Proc Natl Acad Sci U S A, 102(5): 1643-8. [Abstract] [Full-text]
2. The value of PET, CT and in-line PET/CT in patients with gastrointestinal stromal tumours: long-term outcome of treatment with imatinib mesylate.
   Eur J Nucl Med Mol Imaging, 32(2): 153-62. [Abstract] [Full-text]
3. Combination of the histone deacetylase inhibitor LBH589 and the hsp90 inhibitor 17-AAG is highly active against human CML-BC cells and AML cells with activating mutation of FLT-3.
   Blood, 105(4): 1768-76. [Abstract] [Full-text]
4. Activation of the PI3K/mTOR pathway by BCR-ABL contributes to increased production of reactive oxygen species.
   Blood, 105(4): 1717-23. [Abstract] [Full-text]
5. A cell-based screen for resistance of Bcr-Abl-positive leukemia identifies the mutation pattern for PD166326, an alternative Abl kinase inhibitor.
   Blood, 105(4): 1652-9. [Abstract] [Full-text]
6. Targeting the silent minority: emerging immunotherapeutic strategies for eradication of malignant stem cells in chronic myeloid leukaemia.
   Cancer Immunol Immunother, 54(4): 297-306. [Abstract] [Full-text]
7. A non-ATP-competitive inhibitor of BCR-ABL overrides imatinib resistance.
   Proc Natl Acad Sci U S A, 102(6): 1992-7. [Abstract] [Full-text]
8. Imatinib-induced regression of AIDS-related Kaposi's sarcoma.
   J Clin Oncol, 23(5): 982-9. [Abstract] [Full-text]
9. A multitargeted, metronomic, and maximum-tolerated dose "chemo-switch" regimen is antiangiogenic, producing objective responses and survival benefit in a mouse model of cancer.
   J Clin Oncol, 23(5): 939-52. [Abstract] [Full-text]
10. Gastrointestinal stromal tumor of the prostate.
    Urology, 65(2): 388. [Abstract] [Full-text]
11. Carney triad: case report and molecular analysis of gastric tumor.
    Hum Pathol, 36(1): 112-6. [Abstract] [Full-text]
12. Proposal of a morphologic bone marrow response score for imatinib mesylate treatment in chronic myelogenous leukemia.
    Hum Pathol, 36(1): 91-100. [Abstract] [Full-text]
13. Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl.
    Cancer Cell, 7(2): 129-41. [Abstract] [Full-text]
14. AMN107: tightening the grip of imatinib.
    Cancer Cell, 7(2): 117-9. [Abstract] [Full-text]
15. Gastrointestinal stromal tumors: the incidence, prevalence, clinical course, and prognostication in the preimatinib mesylate era--a population-based study in western Sweden.
    Cancer, 103(4): 821-9. [Abstract] [Full-text]
16. Punish the parent not the progeny.
    Blood, 105(5): 1862-6. [Abstract] [Full-text]
17. c-kit Expression in small cell carcinoma of the urinary bladder: prognostic and therapeutic implications.
    Mod Pathol, 18(3): 320-3. [Abstract] [Full-text]
18. Detection of BCR-ABL kinase mutations in CD34+ cells from chronic myelogenous leukemia patients in complete cytogenetic remission on imatinib mesylate treatment.
    Blood, 105(5): 2093-8. [Abstract] [Full-text]
19. Patupilone (epothilone B, EPO906) and imatinib (STI571, Glivec) in combination display enhanced antitumour activity in vivo against experimental rat C6 glioma.
    Cancer Chemother Pharmacol, 55(4): 307-17. [Abstract] [Full-text]
20. A complex translocation (9;22;16)(q34;q11.2;p13) in chronic myelocytic leukemia.
    Cancer Genet Cytogenet, 157(2): 175-7. [Abstract] [Full-text]
21. Clonal evolution with inv(11)(p15q22) and NUP98/DDX10 fusion gene in imatinib-resistant chronic myelogenous leukemia.
    Cancer Genet Cytogenet, 157(2): 104-8. [Abstract] [Full-text]
22. Effect of a p210 multipeptide vaccine associated with imatinib or interferon in patients with chronic myeloid leukaemia and persistent residual disease: a multicentre observational trial.
    Lancet, 365(9460): 657-62. [Abstract] [Full-text]
23. Imatinib pharmacokinetics in patients with gastrointestinal stromal tumour: a retrospective population pharmacokinetic study over time. EORTC Soft Tissue and Bone Sarcoma Group.
    Cancer Chemother Pharmacol, 55(4): 379-86. [Abstract] [Full-text]
24. Global effects of BCR/ABL and TEL/PDGFRbeta expression on the proteome and phosphoproteome: identification of the Rho pathway as a target of BCR/ABL.
    J Biol Chem, 280(8): 6316-26. [Abstract] [Full-text]
25. STI571 (Glivec) inhibits the interaction between c-KIT and heat shock protein 90 of the gastrointestinal stromal tumor cell line, GIST-T1.
    Cancer Sci, 96(2): 116-9. [Abstract] [Full-text]
26. Imatinib mesylate in the treatment of Core Binding Factor leukemias with KIT mutations. A report of three cases.
    Leuk Res, 29(4): 397-400. [Abstract] [Full-text]
27. Modern management of myelofibrosis.
    Br J Haematol, 128(5): 583-92. [Abstract] [Full-text]
28. Imatinib mesylate radiosensitizes human glioblastoma cells through inhibition of platelet-derived growth factor receptor.
    Blood Cells Mol Dis, 34(2): 181-5. [Abstract] [Full-text]
29. BCR/ABL-mediated downregulation of genes implicated in cell adhesion and motility leads to impaired migration toward CCR7 ligands CCL19 and CCL21 in primary BCR/ABL-positive cells.
    Leukemia, 19(3): 373-80. [Abstract] [Full-text]
30. Effects of 17-allylamino-17-demethoxygeldanamycin (17-AAG) on pediatric acute lymphoblastic leukemia (ALL) with respect to Bcr-Abl status and imatinib mesylate sensitivity.
    Pediatr Res, 57(3): 430-7. [Abstract] [Full-text]
31. Innovations in antineoplastic therapy.
    Nurs Clin North Am, 40(1): 77-94. [Abstract] [Full-text]

© 2004-2008 Glivec Research Today. All Rights Reserved.